Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06191822 · ClinicalTrials.gov registry record · NA
Aspire2B Personalization Pilot Study Program
A NA study, sponsored by PepsiCo Global R&D.
- Completed
- Registry status
- NA
- Development phase
- 1,714
- Enrollment target
NCT06191822: Completed NA study, sponsored by PepsiCo Global R&D.
NCT06191822 is a NA study that has completed, run by PepsiCo Global R&D. The registered enrollment target is 1,714 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (22% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06191822, a NA study, has completed, sponsored by PepsiCo Global R&D.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,714 participants
- Enrollment target
Study Summary
This non-randomized pilot study program is focused on assessing the technical characteristics of the Aspire2B mobile device application.
Primary Outcome
Does the app work as intended: Ability to connect wearable devices
Interventions
- OTHER Nutrition
- OTHER Fitness
- OTHER Sleep
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,714 participants |
| Start Date | 2022-03-01 |
| Est. Completion | 2023-09-01 |
| Phase | NA |
What the finished NCT06191822 record still lists
NCT06191822 is an interventional study that assigns participants to a tested intervention. Its 1,714 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (22% higher).
The record links to 0 conditions, and to 3 interventions - of which Nutrition is the first listed.
NCT06191822 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06191822 about?
NCT06191822 is a clinical study titled "Aspire2B Personalization Pilot Study Program". This non-randomized pilot study program is focused on assessing the technical characteristics of the Aspire2B mobile device application.
What is the current status of trial NCT06191822?
This trial is currently completed. It is a NA study. The enrollment target is 1,714 participants. The study started on 2022-03-01. Estimated completion is 2023-09-01.
What interventions are being tested in trial NCT06191822?
The interventions under investigation include: Nutrition (OTHER), Fitness (OTHER), Sleep (OTHER).
Who is sponsoring clinical trial NCT06191822?
This trial is sponsored by PepsiCo Global R&D, which has 47 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06191822's enrollment target sits among peer trials
1,714 62nd of 2000 higher than 1,939 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04291612 · 1,715 participants
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
- NCT05303636 · 1,710 participants · Phase 4
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women
- NCT07304531 · 1,705 participants
First To Know Pregnancy Test - Clinical Evaluation Protocol
- NCT06898034 · 1,725 participants
Postpartum Ultrasound Evaluation to Assess Risk of Hemorrhage
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI